Semaglutide vs Dulaglutide on Epicardial Adipose Tissue

NCT04200625 · Completed

Last updated 2026-05-28

This clinical trial compares the effects of semaglutide and dulaglutide on the thickness of fat around the heart in adults with excess fat around the heart.

Status Completed The study has finished.

Type Observational

Participants 80 people

Who can join Ages 18–90 · all sexes

Timeline Started 2019-09 · est. completion 2019-12

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT04200625 ↗

Description as written by the study sponsor.

Epicardial Fat (EAT), the visceral fat depot of the heart, is a modifiable cardio-metabolic risk factor and therapeutic target. EAT expresses GLP-1 receptors (GLP-1R). GLP-1 receptor agonist liraglutide is known to significantly decrease EAT thickness. However, the effects of GLP-1 receptor agonists semaglutide and dulaglutide on EAT thickness are unknown

Main thing measured	Epicardial Fat thickness
Sponsor	University of Miami
Conditions studied	Epicardial Fat
GLP-1 drugs	semaglutide, dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04200625 ↗